ArticleNature immunology2023
TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer.
Open access · greenAbstract read
In one paragraph
Article in Nature immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 156 papers.
0numbers the graph read from it
0cells of the map it votes in
156citing papers in PubMed
34.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
156 citing papers in PubMed, 210 citations in OpenAlex.
- Trial
- Monocytes acquire a tumor-associated IL1B program upon encountering patient-derived colon cancer organoids.Oncoimmunology · 2026Article
- Mechanisms of tumor cell evasion from NK cell-mediated killing and advances in NK cell-based cancer immunotherapy.Pharmaceutical science advances · 2026Review
- Inhibition of the lipocalin-2-phosphatidylserine axis restores natural killer cell immune surveillance.Cell reports. Medicine · 2026Article
- Tumor-intrinsic IFNγ signaling and niche adaptation drive early colonization in ovarian cancer metastasis.Nature communications · 2026Article
- Spatial and Temporal Heterogeneity of Macrophage Efferocytosis in Tumors: Emerging Implications for Immunotherapy Biomarkers and Therapeutic Timing.Cancer medicine · 2026Review
- TREM2 in glioma: Reprogramming the immune microenvironment from mechanistic understanding to clinical translation (Review).Molecular medicine reports · 2026Review
- Pathophysiological roles of monocytes and macrophages in cancer.Nature reviews. Immunology · 2026Review
- Driving tumor-associated macrophages to a CXCL9Cell reports. Medicine · 2026Article
- 25 Years of Cancer Immunoediting: Dendritic Cells and Macrophages Filled the Missing Gap.Cancers · 2026Review
- A tumor-on-a-chip model reveals and targets reciprocal macrophage-NK cell crosstalk to advance immunotherapy screening.Microsystems & nanoengineering · 2026Article
- TREM2 mediates macrophage suppression of NLRP3 inflammasome pathway to promote non-small cell lung cancer progression.Molecular and cellular biochemistry · 2026Article
- Clonal lineage tracing of innate immune cells in human cancer.Cancer cell · 2026Article
- Targeting immunosuppressive myeloid cells via implant-mediated slow release of small molecules to prevent glioblastoma recurrence.Nature biomedical engineering · 2026Article
- The lethal symbiont: exploring the pathophysiology of cancer.Physiological reviews · 2026Review
- Tumor irradiation promotes antigen dressing of dendritic cells to enhance CAR T cell persistence and efficacy in lung metastases.Nature cancer · 2026Article
- Targeting macrophage-driven NK cell immunosuppression to improve cancer immunotherapy.Journal for immunotherapy of cancer · 2026Review
- Macrophages in lung cancer: principal factors, regulatory mechanisms, and therapeutic opportunities: a narrative review.Translational lung cancer research · 2026Review
- Characterization of natural killer (NK) cells in lung adenocarcinoma and construction of an NK risk signature based on single-cell and macromolecular RNA-seg data.Discover oncology · 2026Article
- Reprogramming T cell-myeloid crosstalk overcomes immune resistance in colorectal cancer.Cell reports. Medicine · 2026Article
96 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 7 institutions in 4 countries.
Matthew D Park *Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ivan Reyes-Torres *Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jessica LeBerichelMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Pauline HamonMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nelson M LaMarcheMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Samarth HegdeMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Meriem BelabedMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Leanna TroncosoMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
John A GroutMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Assaf MagenMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0001-5473-274X
Etienne HumblinMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Achuth NairMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Martina MolgoraDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Jinchao HouDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Jenna H NewmanMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Adam M FarkasMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Andrew M LeaderMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Travis DawsonMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Darwin D'SouzaMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Steven HamelMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Alfonso Rodriguez Sanchez-PauleteMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Barbara MaierMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-7359-6576
Nina BhardwajMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-1865-4187
Jerome C MartinMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-0068-8776
Alice O KamphorstMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ephraim KenigsbergMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-4107-3295
Maria Casanova-AcebesMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-5790-1163
Amir HorowitzMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Brian D BrownMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-3670-8778
Lucas Ferrari De AndradeMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Marco ColonnaDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0001-5222-4987
Thomas U MarronMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0001-5903-8191
Miriam MeradMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. miriam.merad@mssm.edu.ORCID http://orcid.org/0000-0002-4481-7827
Icahn School of Medicine at Mount Sinai · USWashington University in St. Louis · USAustrian Academy of Sciences · ATBrigham and Women's Hospital · USCentre d'Investigation Clinique de Nantes · FRSpanish National Cancer Research Centre · ESTisch Hospital · US
Funding
THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Ramon E Parsons · 2015 to 2026
$35.4MInvestigating Macrophage Molecular and Functional Diversity in Tumor ImmunityR01CA254104 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BROWN, BRIAN D, MERAD, MIRIAM · 2021 to 2025
$3.4MDissecting the pathways driving progenitor to pro-tumor macrophage programmingR01CA257195 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Brian D Brown, MIRIAM MERAD · 2021 to 2026
$3.3MDeterminants of differentiation and maintenance of PD-1+ CD8 T cellsR01AI153363 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KAMPHORST, ALICE OLIFFSON · 2021 to 2025
$3.3MTargeting TREM2 to boost anti-cancer therapyR01CA262684 · NCI · WASHINGTON UNIVERSITY · PI COLONNA, MARCO · 2021 to 2025
$2.1MPromoting immunity against acute myeloid leukemia through Fc effector-optimized antibody inhibitory of MICA/B sheddingR37CA269982 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Lucas Ferrari de Andrade · 2023 to 2026
$2.0MDefining the barriers to immune surveillance in solid tumorsK00CA223043 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HEGDE, SAMARTH · 2020 to 2023
$374kNCI NIH HHS K00 CA223043NCI NIH HHS P30 CA196521NCI NIH HHS R01 CA254104NCI NIH HHS R01 CA257195NCI NIH HHS R01 CA262684NCI NIH HHS R37 CA269982NIAID NIH HHS R01 AI153363
Abstract
Natural killer (NK) cells are commonly reduced in human tumors, enabling many to evade surveillance. Here, we sought to identify cues that alter NK cell activity in tumors. We found that, in human lung cancer, the presence of NK cells inversely correlated with that of monocyte-derived macrophages (mo-macs). In a murine model of lung adenocarcinoma, we show that engulfment of tumor debris by mo-macs triggers a pro-tumorigenic program governed by triggering receptor expressed on myeloid cells 2 (TREM2). Genetic deletion of Trem2 rescued NK cell accumulation and enabled an NK cell-mediated regression of lung tumors. TREM2
Indexed as
Killer Cells, NaturalLung NeoplasmsAnimalsHumansMacrophagesMembrane GlycoproteinsMiceMyeloid CellsReceptors, ImmunologicMembrane GlycoproteinsReceptors, ImmunologicTREM2 protein, humanTrem2 protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.